for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arena Pharmaceuticals, Inc.

ARNA.O

Latest Trade

57.42USD

Change

-1.54(-2.61%)

Volume

319,430

Today's Range

55.43

 - 

58.62

52 Week Range

45.50

 - 

85.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
58.96
Open
58.30
Volume
319,430
3M AVG Volume
10.70
Today's High
58.62
Today's Low
55.43
52 Week High
85.00
52 Week Low
45.50
Shares Out (MIL)
61.33
Market Cap (MIL)
3,615.92
Forward P/E
-5.97
Dividend (Yield %)
--

Next Event

Q4 2021 Arena Pharmaceuticals Inc Earnings Release

Latest Developments

More

Arena Q3 Loss Per Share $3.21

Arena Pharmaceuticals Q2 Loss Per Share $2.40

Arena Reports Q1 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. The Company's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.

Industry

Biotechnology & Drugs

Contact Info

6154 Nancy Ridge Dr

SAN DIEGO, CA

92121-3223

United States

+1.858.4537200

http://www.arenapharm.com/

Executive Leadership

Garry A. Neil

Independent Chairman of the Board

Amit D. Munshi

Director, President, Chief Executive Officer

Laurie D. Stelzer

Chief Financial Officer, Executive Vice President

Joan Schmidt

Executive Vice President, General Counsel, Secretary

Vincent E. Aurentz

Executive Vice President, Chief Business Officer

Key Stats

1.69 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.8K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.630

2019

7.690

2020

-7.390

2021(E)

-9.876
Price To Earnings (TTM)
--
Price To Sales (TTM)
97,727.51
Price To Book (MRQ)
4.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.29
LT Debt To Equity (MRQ)
4.68
Return on Investment (TTM)
-56.29
Return on Equity (TTM)
-53.57

Latest News

Latest News

BRIEF-Arena Pharmaceuticals Says Board Increased Size Of Board To 9 Directors - SEC Filing

* ARENA PHARMACEUTICALS SAYS BOARD INCREASED SIZE OF BOARD FROM 8 DIRECTORS TO 9 DIRECTORS - SEC FILING Source text: https://bit.ly/2Yc3Trb Further company coverage:

BRIEF-Arena Pharmaceuticals Appoints Biotech Executive Katharine Knobil To Board Of Directors

* ARENA PHARMACEUTICALS APPOINTS BIOTECH EXECUTIVE KATHARINE KNOBIL, M.D., TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Arena Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* ARENA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Arena Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* ARENA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Arena Pharmaceuticals Q1 Loss Per Share $2.00

* ARENA ANNOUNCES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Arena Pharma Announces Positive Topline Data For New Development Program

* ARENA PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE DATA FOR NEW DEVELOPMENT PROGRAM - ETRASIMOD CONTROLLED-RELEASE (CR)

BRIEF-Arena Posts Quarterly Loss Per Share Of $1.76

* ARENA ANNOUNCES MANAGEMENT AND PROGRAM UPDATES AND REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

Arena Pharma soars on deal with United Therapeutics for hypertension drug

Shares of Arena Pharmaceuticals Inc jumped nearly 30 percent after the drug developer sold rights to develop and sell its hypertension treatment to United Therapeutics Corp, fetching it $800 million in an upfront payment.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up